Fertility What is Bisorb®? The Bisorb®  is a a revolutionary mode of topical drug delivery in the management of CRS, enabling targeted, sustained release of corticosteroids  directly to sinonasal mucosa with simultaneous stenting of the postsurgical sinus cavity. Ethmoidal Placement Maxillary Placement Frontal Placement  (Draf 3) The middle of the stent can be filled with "finger sleeve" Frontal recess Placement Fixed mucosal flap Clinical evidence-Clinical trial  50+ POST-OPERATIVE
INTERVENTION Conclusions:  Bisorb®  Reduced  Inflammation, Polyp formation and Need for Additional Surgery . improving surgical outcoms——ethmoid sinus The Bisorb® implant is comprised of a biodegradable PLG  polymer matrix coated with 652 μg of mometasone furoate(MF) in a spring-like fashion, which is gradually eluted over a 30-day period. What is Bisorb®? Bisorb®  Drug-eluting Sinus Absorbable Stent System Specification How It Works How It Works How It Works How It Works Zhenxiao Huang , Bing Zhou, Dehui Wang,Hongrui Zang,  Huankang Zhang, Huan Wang,Shenqing Wang, Lei Cheng, Jinrang Li, Wenying Wu,Huifang Zhou, and Huili Wu. Comparison of Bioabsorbable Steroid-Eluting Sinus Stents Versus Nasopore After Endoscopic Sinus Surgery: A Multicenter, Randomized, Controlled, Single-Blinded Clinical Trial . Ear, Nose & Throat J. 2022 May;101(4):260-267. SEVERE ADHESIONS
INFLAMMATION POLYPOSIS
Zhenxiao Huang , Bing Zhou, Dehui Wang,Hongrui Zang,  Huankang Zhang, Huan Wang,Shenqing Wang, Lei Cheng, Jinrang Li, Wenying Wu,Huifang Zhou, and Huili Wu. Comparison of Bioabsorbable Steroid-Eluting Sinus Stents Versus Nasopore After Endoscopic Sinus Surgery: A Multicenter, Randomized, Controlled, Single-Blinded Clinical Trial . Ear, Nose & Throat J. 2022 May;101(4):260-267. Bioabsorbable steroid-eluting sinus stents for patients with refractory frontal diseases undergoing a revision Draf 3  procedure: a case series .
Case 1
Zhenxiao Huang, Qian Huang, Bing Zhou, Jingying Ma, Mingjie Wang & Yi Dong .Bioabsorbable steroid-eluting sinus stents for patients with refractory frontal diseases undergoing a revision Draf 3 procedure: a case series. Acta Otolaryngol. 2019 Jul;139(7):636-642. Conclusions:   Bisorb®  Drug-eluting sinus stents may decrease recurrence rates in revision cases   where patients have extensive scarring or neo-osteogenesis of the operative field from prior Draf 2 or 3 procedures.
Conclusions:   Bisorb®  Drug-eluting sinus stents reduce postoperative sinus mucosal edema, and eosinophilic inflammation, with persistent effects after stent disintegration,and are a good supplementary postsurgical treatment in patientswith ECRSwNP. improving surgical outcoms——frontal sinus improving surgical outcoms——ECRS Comparison of type 2 inflammatory mediators between the stent group and control group. ESS, endoscopic sinus surgery; ns, no significance.
*P < .05. ****P < .0001. Conclusions:   Bisorb®  Drug-eluting sinus stent is an effective treatment for olfactory deficits in patients with CRSwNP and may be related to the stent’s more effective reduction of local type 2 inflammatory mediators in the nasal cavity. improving surgical outcoms——CA